Navigation Links
Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
Date:11/7/2009

s, 11 hours for abdominal, 24 hours for facial and 25 hours for peripheral attacks. No drug-related serious adverse events have been reported to date, nor were any rebound effects observed following C1-INH administration.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.

    Contact:
    Sheila A. Burke, Director, Communications & Public Relations
    Worldwide Commercial Operations
    CSL Behring
    C: 484-919-2618
    O: 610-878-4209
    Sheila.Burke@cslbehring.com

SOURCE CSL Behring


'/>"/>
SOURCE CSL Behring
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies
7. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
8. Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 OmPrompt ... Millionen £ investiert hat, um die weltweite ... Pharma- und Logistikbranche zu erfüllen. Albion wird ... (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... sein beschleunigtes Wachstum mit Investitionen in seine ...
(Date:7/28/2014)... VILLAGE, Nev. , July 28, 2014 PDL ... that the Company will release its second quarter 2014 financial ... August 11, 2014, after market close. PDL,s management will host ... Eastern Time to discuss the financial results.  A slide presentation ... link on the PDL website. Conference Call Details ...
(Date:7/28/2014)... Germany and LONDON ... , Collaboration aims to create and commercialize companion ... the use of IRESSA  for non-small cell lung cancer ... QIAGEN,s FDA-approved  therascreen   EGFR test and is planned to run on ... instruments  Project enabled by AstraZeneca master framework ...
Breaking Medicine Technology:OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... Consumer Healthcare Products Association (CHPA) released the following ... passing a real-time, stop-sale system that allows law-abiding ... pseudoephedrine (PSE), while stopping sales that exceed the ... real-time, stop-sale system is a victory for law-abiding ...
... HeartWare International, Inc. (NASDAQ: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... Eastern Time on Wednesday, June 22, 2011.  The conference ...
Cached Medicine Technology:HeartWare to Present at the Wells Fargo 2011 Healthcare Conference 2
(Date:7/28/2014)... new study, published in the July, 2014, issue ... Institute by Northwestern Medicine researchers, sheds new ... popularity of endoscopic resection in the treatment of ... more traditional surgical resection, while more invasive, provided ... survival rate for patients than endoscopic resection, which ...
(Date:7/28/2014)... Smart phones and mobile devices are on the cusp ... apps capable of providing everything from cardiac measurements to ... to medical treatment and control costs, several health law ... of Medicine (NEJM) report that more oversight is ... to ensure consumer confidence and safety. Out of some ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A young ... to the all-too-often stories in the media today about ... occur in a matter of minutes in a hot ... to the Office of Emergency Medical Services at NHTSA. ... app for smartphones. Realizing that it’s all too easy ...
(Date:7/28/2014)... Abington, PA (PRWEB) July 28, 2014 ... solutions provider for the healthcare industry, went live in ... and surpassed the basic standards of excellence that comprise ... specifically for excellence in Healthcare. , “What pleases me ... both the content and usability categories,” said Joshua Snow, ...
(Date:7/28/2014)... 2014 Irresistible infants have met their match with ... The online gifting company specializes in homemade chicken noodle soup and ... Baby package starts with home-from-the-hospital essentials every new parent will love:, ... 6 rolls , 6 cookies , a ... is ready to heat and eat upon delivery, so parents can ...
Breaking Medicine News(10 mins):Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Booming mobile health app market needs more FDA oversight for consumer safety, confidence 2Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2Health News:Abington Health Website Named Best in Class 2Health News:Spoonful of Comfort Announces "New Baby" Gift Package 2
... genetic links, but urge further study , WEDNESDAY, Oct. ... that might be associated with autism have been identified ... a single-letter change on chromosome 5 near a gene ... the growth of neurons and their long progressions, called ...
... 7 Each year, an estimated 800,000 ... in which the victims survive, but their lives, and ... Brain injury victims can suffer from a multitude of ... depression and sleep disturbances. , Careforward , ...
... Crawford & Company,s (NYSE: CRDA ; CRDB) ... under the brand name of Broadspire, a Crawford company, ... , Crawford (NYSE: CRDA ; CRDB), the world,s ... latest expansion of the Broadspire brand at the Federation ...
... Healthcare, one of the nation,s first and leading providers ... nephrology research, today announced their sponsorship of the National ... , The Author,s Luncheon is San Francisco,s premier ... captivated by the fascinating stories, wit and humor of ...
... , BOCA RATON, Fla., Oct. 7 Coverall Health-Based Cleaning ... announced it has been recognized as one of the ... Franchising Initiative (NMFI) for the third year in a ... "Franchising Today" section of USA Today, the national daily ...
... Henry Ford Hospital have identified tumor-suppressing genes that may ... survival for laryngeal cancer patients than current standards. ... specific receptor 1) gene and the HIC1 (hypermethylated in ... and shorter survival, respectively, for patients with the disease. ...
Cached Medicine News:Health News:Potential Pieces of Autism Puzzle Revealed 2Health News:Mingling, Martinis & Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 2Health News:Crawford & Company's Broadspire Unit Continues Its European Expansion 2Health News:Satellite Healthcare Partners With the National Kidney Foundation for the 21st Annual San Francisco Author's Luncheon 2Health News:Coverall Named Among '50 Top Franchises for Minorities' for Third Consecutive Year 2Health News:Genes signal late-stage laryngeal cancer, poorer outcome 2
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... Unique to the Medtronic Hall, the aortic and ... In the aortic position, the disc opens to ... valve opens to 70 to minimize regurgitation. Designed ... the surgeon to align the leading edge of ...
... Pipettor , , The Shortyavailable with both ... how our face-to-face relationship with the scientific community ... make pipetting easier and more effective., Shorter ... Gets you closer to the working area ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: